Vaccinations in RA: Stay Healthy!

Vaccinations

Vaccinations are a critical component of RA clinical management, and their importance in preventing infection cannot be stressed enough. The majority of patients with RA are on immunosuppressive treatment, and a data driven approach to vaccinations in this high-risk population is essential.

FDA Approves Tocilizumab for Treatment of Rheumatoid Arthritis

On January 8, 2010, the U.S. Food and Drug Administration approved tocilizumab (to be marketed under the trade name of Actemra) for the treatment of patients with moderate to severe rheumatoid arthritis who have had inadequate clinical responses to treatment with TNF inhibitors.  Tocilizumab is a humanized monoclonal antibody directed against the receptor for IL-6, […]

Swefot Trial Suggests Adding TNF Inhibitor Better than Triple Therapy in RA Patients who do not Rapidly Respond to Methotrexate

Initial combination therapy has been shown to be superior to step-up combination therapy in groups of RA patients; however, these findings are difficult to reconcile with the observation that many RA patients will have complete remission of disease on methotrexate alone. Practice patterns tend to emphasize initial treatment with methotrexate monotherapy, followed by the addition of other agents in combination for those with inadequate responses.

Arthritis News: Golimumab Receives FDA Approval

FDA

Approval for golimumab (which will by marketed under the trade name Simponi) was granted this week by the U.S. Food and Drug Administration.  The drug received approval for the treatment of moderate to severe RA (in conjunction with methotrexate), active psoriatic arthritis (as monotherapy or with methotrexate), and active ankylosing spondylitis at a dose of […]

New Onset Psoriasis may be Increased in TNF Inhibitor User

02-20-2009-plaque-psoriasis

Cases of new onset psoriasis in patients receiving TNF inhibitors for the treatment of rheumatoid arthritis (RA) have been reported; however, case reports do not permit the calculation of drug-associated incidence rates.  Here, Harrison et al (Ann Rheum Dis 2009; 68: 209) compare incident psoriasis in TNF inhibitor treated vs. untreated patients enrolled in the […]